There are no commercially available effective antiviral medications or vaccines to deal with
novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for …

Abstract Coronavirus disease (COVID-19) was first reported in December 2019, China and
later it was found that the causative microorganism is severe acute respiratory syndrome …

The new coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), can present neurological symptoms and induce …

For COVID-19 survivors, defeating the virus is just the beginning of a long road to recovery.
The inducibility and catastrophic effects of the virus are distributed across multiple organs …

This study aims to provide guidelines to design and perform a robust and reliable physical-
chemical characterization of liposome-based nanomaterials, and to support method …

Aim: To examine the therapeutic/preventive potential of liposome-encapsulated
spironolactone (SP; Lipo-SP) for acute lung injury (ALI) and fibrosis. Materials & methods …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is causing an ongoing
pandemic of coronavirus disease 2019 (Covid‐19). Effective therapies are required for the …

High-density lipoproteins (HDLs) have multiple endothelioprotective properties. During
SARS-CoV-2 infection, HDL-cholesterol (HDL-C) concentration is markedly reduced, and …

Some of the most significant medical achievements in recent history are the development of
distinct and effective vaccines, and the improvement of the efficacy of previously existing …

The encapsulation of drugs into liposomes aims to enhance their efficacy and reduce their
toxicity. Corticosteroid-loaded liposomes are currently being evaluated in patients suffering …